VX 634
Alternative Names: VX-634Latest Information Update: 22 Mar 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Alpha 1-antitrypsin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alpha 1-antitrypsin deficiency
Most Recent Events
- 13 Nov 2023 Vertex Pharmaceuticals Incorporated completes a phase-I trials in Alpha 1-antitrypsin deficiency (In volunteers) in USA (PO) (NCT05579431)
- 27 Oct 2022 Vertex Pharmaceuticals plans a phase II trial for Alpha 1-antitrypsin deficiency
- 11 Oct 2022 Phase-I clinical trials in Alpha 1-antitrypsin deficiency (In volunteers) in USA (PO) (NCT05579431)